AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$URGN

Schoenberg Mark sold $2.9M of URGN

Schoenberg Mark (Chief Medical Officer) sold 60,677 shares of UroGen Pharma Ltd. (URGN) at $47.05 ($2.85M total) on 2026-08-20.

Original reporting
SEC EDGAR · Schoenberg Mark
Published Aug 24, 2026, 9:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$URGN
Bearish
medium confidence
Mentioned
$URGN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$URGNBearishLow
01

Why it matters

The reduction in insider ownership may be interpreted as a lack of confidence, influencing short‑term sentiment.

02

Market read

Insider sell adds a modest negative bias to URGN, relevant for short‑term traders.

03

What to watch

Potential upcoming clinical data releases that could offset the sell pressure.

Relevance 6/10Novelty 7/10Timing: today

Background

Form 4 filing discloses insider transactions; such filings are primary sources of material insider activity.

Company-level read

Ticker impact

$URGNBearishMedium confidence
Context

Chief Medical Officer sold 60,677 shares for $2.85M, reducing his stake to 59,086 shares.

Expected impact

Possible short-term dip of 2-4% as market digests the sell.

Evidence & confidence

The sale is sizable for a micro‑cap biotech and comes from a senior executive, but no accompanying guidance change.

Market effects

Sector

May weigh on other biotech stocks as investors scrutinize insider activity.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Officer
    Schoenberg Mark

    Chief Medical Officer of UroGen Pharma Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

URGN insider trading history →

Related articles

AUG 12
$URGNMedAI 8/10

UroGen (URGN) Q2 2026 Earnings Call Transcript

UroGen Pharma (URGN) reported Q2 2026 revenue of $72.5 million, up from $24.2 million a year earlier, driven by ZUSDURI commercial launch. ZUSDURI revenue was $50.4 million, up 73% vs Q1 2026. JELMYTO revenue was $22.0 million. Net loss was $14.4 million. Cash was $108 million. 2026 operating expense guidance is $260-$270 million; JELMYTO revenue guidance is $97-$101 million.

fool.com7 min
AUG 5
$URGNMed

UroGen Pharma Ltd. (URGN): Results of Operations and Financial Condition

UroGen Pharma Ltd. (URGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 UroGen Reports $50.4 Million of ZUSDURI ® Revenue and Provides Second Quarter 2026 Financial Results and Highlights ● ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth ● Once issued, new U.S. pate

SEC EDGAR 8-K6 min
JUL 8
$URGNMedAI 8/10

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd. (Nasdaq: URGN) said the FDA cleared its IND for UGN-501, an investigational oncolytic virus for non-muscle invasive bladder cancer. The clearance allows initiation of a planned Phase 1 trial of intravesical UGN-501, with patient enrollment expected to start in Q4 2026 to assess safety, tolerability, and feasibility.

manilatimes.net2 min